AUG 04, 2019 10:32 AM PDT

Does Microdosing Really Boost Productivity and Creativity?

WRITTEN BY: Annie Lennon

Microdosing is the practice of ingesting very low doses of psychedelic substances, typically a twentieth of a recreational dose. In particular, Lysergic acid and diethylamine (LSD) and psilocybin have become more popular in recent years for microdosing as people have reported feeling increases in productivity, creativity and general well being. But how effective is it? 

Research on microdosing is relatively scarce, with few, if any, experimental studies and peer-reviewed research due to current legal and bureaucratic climates. Despite this however, observational studies and interview-based studies have been conducted and provide some insight into the potential of the practice (Anderson: 2018). 

Reports of the practice are generally positive. For example, research in 2018 taken interviewing microdosers found generally positive outcomes included better mood, higher energy levels and better cognition (Johnstad: 2018). Other studies have found that microdosing leads to increases in convergent and divergent thinking- key indicators of creativity, as well as a reduced levels of negative thinking and emotions, increased wisdom and more open-mindedness than those who had not microdosed (Prochazkova: 2018, Anderson: 2018). 

A study published in February 2019 however challenged these findings. Although a self-reported observational study, and thus limited in scope, it likewise reported general positive outcomes from the practice, researchers found that many of its immediate effects including boosts in productivity and creativity were short-lived, and were not sustained beyond the day of dosing (Polito: 2019). 

Instead however, it was found that longer-term effects included reduced mental distress and changes in constructs including absorption and mind wandering. This suggested that expectations from popular belief (that microdosing leads to sustained increases in productivity and creativity) have little effect on real outcomes and that instead, longer term outcomes lead to more subtle changes in improving mental stability, focus, and the ability to become engaged by intense imaginative experiences. 

Unexpected by the researchers, they also found that despite these positive outcomes, neuroticism also tended to increase after microdosing. Although most of the participants’ comments were positive following their experiences, some reflected unease. This highlights that, even though microdosing may have positive benefits for many, it is still not a panacea to everyday issues, and may not be universally beneficial. 

As microdosing is generally under-researched, there is little confirmation on its safety, although more extensive research on people taking higher doses suggests that it is likely a safe practice. This comes in accordance with large scale population studies finding no association between psychedelics and negative mental health, as well as their property as non-addictive substances (ibid.). 

To conclude, it is difficult to be certain whether or not microdosing has significant long term benefits due to current legal and bureaucratic climates making it hard to properly conduct research. Despite this however, the majority of research so far on the subject has been positive, although expectations on its utility alone as a panacea should perhaps be avoided. After all, although it may not specifically lead to sustained increases in productivity and creativity in business settings, it may instead lead to more subtle positive outcomes related to general mental health. 

 

Sources 

 

Anderson, Thomas: Research Gate 

Johnstad, Petter Grahl, SAGE 

Prochazkova, Luisa, Springer

Andersson, T.: Pub Med 

Polito, Vince et al. Macquarie University 

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
SEP 27, 2020
Cannabis Sciences
THC Shows Promise in Treating Severe Cases of COVID-19
SEP 27, 2020
THC Shows Promise in Treating Severe Cases of COVID-19
Over the last few months, various headlines have emerged suggesting the potential for cannabinoids, and in particular, c ...
OCT 21, 2020
Drug Discovery & Development
Experimental Vaccine Shows Promise in Halting Alzheimer's
OCT 21, 2020
Experimental Vaccine Shows Promise in Halting Alzheimer's
In a preclinical study, researchers from the Univerity of South Florida have found that a vaccine that targets neurotoxi ...
NOV 02, 2020
Immunology
New Cancer Drug Reboots Stalled Immunotherapies
NOV 02, 2020
New Cancer Drug Reboots Stalled Immunotherapies
In contrast to traditional chemotherapies, immunotherapies reprogram the patient’s own immune system to fight tumo ...
NOV 11, 2020
Cancer
A New CDK Inhibitor Could Help with Unresponsive Liver Cancer
NOV 11, 2020
A New CDK Inhibitor Could Help with Unresponsive Liver Cancer
Amongst the most common targets of anti-cancer drugs are small regulatory molecules called cyclin-dependent kinases (CDK ...
NOV 09, 2020
Drug Discovery & Development
New Immunotherapy Shows Promise for MS
NOV 09, 2020
New Immunotherapy Shows Promise for MS
Researchers from Thomas Jefferson University in Philadelphia are studying an immunotherapy that has shown early pro ...
NOV 20, 2020
Drug Discovery & Development
Cat Parasite Gives Clues on New Drug Targets for Schizophrenia
NOV 20, 2020
Cat Parasite Gives Clues on New Drug Targets for Schizophrenia
Researchers from the UK and France have discussed a mechanism of action behind the infamous Toxoplasma gondii  ...
Loading Comments...